CAPR
NASDAQ
US
Capricor Therapeutics, Inc. - Common Stock
$32.11
▲ +$1.99
(+6.61%)
Vol 1.2M
5
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$1.6B
ROE
-71.0%
Margin
-181.7%
D/E
4.03
Beta
0.74
52W
$4–$40
Wall Street Consensus
16 analysts · Apr 20264
Strong Buy
11
Buy
1
Hold
0
Sell
0
Strong Sell
93.8%
Buy Rating
Price Chart
Similar Stocks
CLDX
Celldex Therapeutics Inc
$1.8B
AGIO
Agios Pharmaceuticals Inc
$1.6B
SLNO
Soleno Therapeutics Inc
$2.5B
STOK
Stoke Therapeutics Inc
P/E 44.2
$1.8B
VRDN
Viridian Therapeutics Inc
$3.0B
SION
Sionna Therapeutics Inc
$1.8B
VCEL
Vericel Corp
P/E 139.2
$1.8B
PVLA
Palvella Therapeutics Inc
$1.2B
ZYME
Zymeworks Inc
$2.0B
Earnings
Beat rate: 40.0%
Next Report
May 11, 2026
EPS Estimate: $-0.49
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.49 | — | — |
| Dec 2025 | $-0.55 | $-0.62 | $-0.07 |
| Sep 2025 | $-0.56 | $-0.54 | +$0.02 |
| Jun 2025 | $-0.48 | $-0.57 | $-0.09 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | $2.3M | $11.1M | — | — | — | — |
| Net Income | -$12.6M | -$7.1M | -$24.4M | -$25.9M | -$24.6M | — |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -62.7% | -62.7% | -62.7% | -62.7% | -71.0% | -71.0% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | -181.7% | -181.7% | -181.7% | -181.7% | -181.7% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 3.22 | 3.22 | 3.22 | 3.22 | 4.03 | 4.03 |
| Current Ratio | 4.37 | 4.37 | 4.37 | 4.37 | 3.59 | 3.59 |
Key Ratios
ROA (TTM)
-56.1%
P/S (TTM)
70.50
P/B
4.3
EPS (TTM)
$-1.80
CF/Share
$-1.11
Rev Growth 3Y
+352.7%
52W High
$40.37
52W Low
$4.30
$4.30
52-Week Range
$40.37
Financial Health
Free Cash Flow
-$23.7M
Net Debt
-$5.0M
Cash
$19.5M
Total Debt
$14.5M
As of Sep 30, 2025
How does CAPR compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
CAPR valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
70.5
▲
449%
above
peers
(12.9)
vs Peers
vs Industry
Pricier
P/B ratio
4.3
▲
75%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
CAPR profitability vs Biotechnology peers
ROE
-71.0%
▼
5%
below
peers
(-67.3%)
vs Peers
vs Industry
In line
Net margin
-181.7%
▲
37%
above
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-56.1%
▼
20%
below
peers
(-46.7%)
vs Peers
vs Industry
Below avg
CAPR financial health vs Biotechnology peers
D/E ratio
4.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
3.6
▼
19%
below
peers
(4.4)
vs Peers
vs Industry
Below avg
Beta
0.7
▼
24%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
CAPR fundamentals radar
CAPR
Peer median
Industry
CAPR profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
CAPR vs peers: key metrics
Top Holders
Top 5: 18.67%Blackrock Inc.
4.96%
$82.4M
Vanguard Group Inc
4.45%
$74.0M
Point72 Asset Management, L…
3.20%
$53.2M
Suvretta Capital Management…
3.10%
$51.6M
Tang Capital Management, LLC
2.96%
$49.1M
As of Dec 31, 2025